{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:41:19Z","timestamp":1789065679875,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070581"],"award-info":[{"award-number":["82070581"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130017"],"award-info":[{"award-number":["82130017"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81790634"],"award-info":[{"award-number":["81790634"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830016"],"award-info":[{"award-number":["81830016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["SHDC2022CRT002"],"award-info":[{"award-number":["SHDC2022CRT002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81620108002"],"award-info":[{"award-number":["81620108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2507500"],"award-info":[{"award-number":["2023YFC2507500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jaut.2023.103163","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T12:03:14Z","timestamp":1706702594000},"page":"103163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis"],"prefix":"10.1016","volume":"143","author":[{"given":"Rui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolian","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuchen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengrui","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuxiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9616-4672","authenticated-orcid":false,"given":"Xiong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2023.103163_bib1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2023.103163_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"The diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2023.103163_bib3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2023.103163_bib4","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients","volume":"122","author":"Corpechot","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2023.103163_bib5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2023.103163_bib6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cgh.2013.09.021","article-title":"Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis","volume":"12","author":"Ozaslan","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2023.103163_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102328","article-title":"The challenges of primary biliary cholangitis: what is new and what needs to be done","volume":"105","author":"Terziroli Beretta-Piccoli","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2023.103163_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cld.2022.06.007","article-title":"The inconvenient truth of primary biliary cholangitis\/autoimmune hepatitis overlap syndrome","volume":"26","author":"Hussain","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.jaut.2023.103163_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051449","article-title":"Treatment of overlap syndromes in autoimmune liver disease: a systematic review and meta-analysis","volume":"9","author":"Freedman","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jaut.2023.103163_bib10","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2023.103163_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2023.103163_bib12","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should Be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2023.103163_bib13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group","volume":"76","author":"Pape","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2023.103163_bib14","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2023.103163_bib15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2023.103163_bib16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jhep.2007.07.006","article-title":"Grading and staging systems for inflammation and fibrosis in chronic liver diseases","volume":"47","author":"Goodman","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2023.103163_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement","volume":"60","author":"Nakanuma","year":"2010","journal-title":"Pathol. Int."},{"key":"10.1016\/j.jaut.2023.103163_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2023.103163_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/08916934.2013.801461","article-title":"Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease","volume":"46","author":"Gatselis","year":"2013","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaut.2023.103163_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis","volume":"8","author":"Hirschfield","year":"2013","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.jaut.2023.103163_bib21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.32405","article-title":"Mechanisms and molecules: what are the treatment targets for primary biliary cholangitis?","volume":"76","author":"Mayo","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2023.103163_bib22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0168-8278(92)90065-W","article-title":"A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results","volume":"15","author":"Mitchison","year":"1992","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2023.103163_bib23","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2023.103163_bib24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2023.103163_bib25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2023.103163_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2023.103163_bib27","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2023.103163_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-021-10276-6","article-title":"APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis","volume":"16","author":"You","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jaut.2023.103163_bib29","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2023.103163_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaut.2012.10.004","article-title":"Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis","volume":"41","author":"Wang","year":"2013","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2023.103163_bib31","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2023.103163_bib32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouill\u00e8res","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2023.103163_bib33","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841123001725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841123001725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:33:09Z","timestamp":1778700789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841123001725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":33,"alternative-id":["S0896841123001725"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2023.103163","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2023.103163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103163"}}